Fast-growing Oligodendrogliomas Are Aggressive Tumors-the Real Life Biomarker?

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2020 Apr 17

PMID 32296823

Authors

Marjolein Geurts

Martin J van den Bent

Affiliations

Soon will be listed here.

References

Wijnenga M, French P, Dubbink H, Dinjens W, Atmodimedjo P, Kros J . The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro Oncol. 2017; 20(1):103-112. PMC: 5761503. DOI: 10.1093/neuonc/nox176. View

Wijnenga M, French P, Dubbink H, Dinjens W, Atmodimedjo P, Kros J . Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma. J Neurooncol. 2018; 139(2):349-357. PMC: 6096891. DOI: 10.1007/s11060-018-2867-8. View

Halani S, Yousefi S, Velazquez Vega J, Rossi M, Zhao Z, Amrollahi F . Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways. NPJ Precis Oncol. 2018; 2:24. PMC: 6219505. DOI: 10.1038/s41698-018-0067-9. View

Etxaniz O, Carrato C, de Aguirre I, Queralt C, Munoz A, Ramirez J . IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas. J Neurooncol. 2017; 135(2):273-284. DOI: 10.1007/s11060-017-2570-1. View

Figarella-Branger D, Mokhtari K, Dehais C, Jouvet A, Uro-Coste E, Colin C . Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations. Neuro Oncol. 2014; 16(9):1244-54. PMC: 4136899. DOI: 10.1093/neuonc/nou047. View

Appay R, Dehais C, Maurage C, Alentorn A, Carpentier C, Colin C . CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol. 2019; 21(12):1519-1528. PMC: 7145561. DOI: 10.1093/neuonc/noz124. View

Roux A, Tauziede-Espariat A, Zanello M, Peeters S, Zah-Bi G, Parraga E . Imaging growth as a predictor of grade of malignancy and aggressiveness of IDH-mutant and 1p/19q-codeleted oligodendrogliomas in adults. Neuro Oncol. 2020; 22(7):993-1005. PMC: 7339891. DOI: 10.1093/neuonc/noaa022. View

Pallud J, Blonski M, Mandonnet E, Audureau E, Fontaine D, Sanai N . Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol. 2013; 15(5):595-606. PMC: 3635513. DOI: 10.1093/neuonc/nos331. View

Mandonnet E, Delattre J, Tanguy M, Swanson K, Carpentier A, Duffau H . Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003; 53(4):524-8. DOI: 10.1002/ana.10528. View

10.

Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T . Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol. 2017; 20(1):66-77. PMC: 5761527. DOI: 10.1093/neuonc/nox132. View

11.

Reuss D, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, Kratz A . IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. 2015; 129(6):867-73. PMC: 4500039. DOI: 10.1007/s00401-015-1438-8. View